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ABSTRACT
Thrombus formation is initiated by platelets and leads to cardiovascular, cerebrovascular, and pe-
ripheral vascular disease, the leading causes of morbidity and mortality in the Western world. A
number of antiplatelet drugs have improved clinical outcomes for thrombosis patients. However,
their expanded use, especially in surgery, is limited by hemorrhage. Here, we describe an antiplatelet
agent that can have its activity controlled by a matched antidote. We demonstrate that an RNA ap-
tamer targeting von Willebrand factor (VWF) can potently inhibit VWF-mediated platelet adhesion
and aggregation. By targeting this important adhesion step, we show that the aptamer molecule can
inhibit platelet aggregation in PFA-100 and ristocetin-induced platelet aggregation assays. Further-
more, we show that a rationally designed antidote molecule can reverse the effects of the aptamer
molecule, restoring platelet function quickly and effectively over a clinically relevant period. This ap-
tamer-antidote pair represents a reversible antiplatelet agent inhibiting a platelet specific pathway.
Furthermore, it is an important step towards creating safer drugs in clinics through the utilization of
an antidote molecule.
INTRODUCTION
PLATELETS are anuclear, disk-shaped cells that play akey role in hemostasis and thrombosis. They survey
the blood vessels, arrest bleeding around areas of damage
and are a critical factor in maintaining hemostasis. How-
ever, they can also lead to thrombosis, which is the lead-
ing cause of morbidity and mortality in the Western
world (Jackson and Schoenwaelder, 2003; Thom et al.,
2006).
In the last 20 years, a number of antiplatelet drugs have
emerged as more information about platelet biology re-
vealed novel targets for therapeutic inhibition. Although
these agents have had a major impact on reducing the
complications of cardiovascular disease, their therapeutic
effect is incomplete for many high-risk patients (Bhatt
and Topol, 2003; Jackson and Schoenwaelder, 2003).
Many of these drugs have been directed at a specific
pathway in platelet activation (i.e., aspirin and clopido-
grel). A fundamental problem with targeting a specific
pathway is that platelet aggregation can still occur via al-
ternate pathways, leading to a relatively mild antithrom-
botic effect. It is estimated that approximately 8%–18%
of patients treated with aspirin experience recurrent vas-
cular events after 2 years (Mason et al., 2005). Although
platelet receptor glycoprotein IIb-IIIa (GP IIb-IIIa) inhib-
itors overcome this problem by targeting the final com-
mon pathway in platelet activation, their therapeutic effi-
cacy is limited by bleeding at peak concentrations and
subtherapeutic activity at lower doses (Wu et al., 2002a).
Furthermore, none of the current antiplatelet therapies
prevent the initiating step for thrombus formation:
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platelet adhesion (Bhatt and Topol, 2003; Jackson and
Schoenwaelder, 2003). The current classes of antiplatelet
agents (aspirin, thienopyridines, and the glycoprotein
IIb/IIIa inhibitors) target metabolic or aggregatory prop-
erties of platelets, but do little to interfere with platelet-
vessel wall interactions; it is in these interactions that
circulating von Willebrand factor (VWF) and subendo-
thelial matrix proteins play an important role.
VWF is a multimeric plasma glycoprotein that is criti-
cal for primary hemostasis. It plays a direct role in allow-
ing platelet attachment to sites of vascular injury through
their GP Ib-IX-V receptors and aids in platelet plug for-
mation by enabling platelet–platelet interactions through
GP IIb-IIIa (Ruggeri et al., 1999; Ruggeri 2003). Qualita-
tive or quantitative deficiencies of VWF can lead to von
Willebrand’s disease (VWD), in which patients present
with a mild to severe bleeding phenotype (Sadler 2005a,
2005b). Numerous studies have shown that inhibiting the
VWF–GP Ib-IX-V interaction using antibodies can de-
crease arterial thrombosis in animal models, but these ap-
proaches have serious shortcomings that impede their
clinical development (Miller et al., 1991; Cadroy et al.,
1994; Chang et al., 1998; Yamamoto et al., 1998;
Cauwenberghs et al., 2000; Wu et al., 2002; Bhatt and
Topol, 2003; Jackson and Schoenwaelder, 2003). None
of these molecules are reversible, and at doses that can
effectively inhibit VWF activity, they transiently engen-
der a VWD-disease state that can cause severe bleeding,
thus undermining patient safety (Cadroy et al., 1994; Ya-
mamoto et al., 1998; Wu et al., 2002). The fact that VWD
results in patients with bleeding disorders who may re-
quire medical therapy certainly validates VWF as an at-
tractive target for platelet inhibition, but one that would
require stringent control so as to provide clinical benefit
without the risk of hemorrhage.
The case for antidote control of antiplatelet agents is
no clearer than in the surgical arena where minimizing
comorbidities improves outcomes. Many patients taking
aspirin and clopidorel are advised to stop taking their
medication 7–10 days prior to surgery so as to prevent
bleeding complications. This places the patient at risk for
thrombosis and creates a therapeutic dilemma for sur-
geons. Moreover, a number of studies have shown that
coupling antiplatelet agents with anticoagulant therapies
can improve patient outcomes but carries a significant
risk of hemorrhage (Huynh et al., 2001). It is this in-
creased risk of major bleeding that lowers the clinical
benefit of such combination therapies. An antidote-con-
trolled antiplatelet drug would provide the flexibility of
protecting the patient from thrombotic complications and
allow for rapid reversal of the drug’s activity in a life-
threatening hemorrhage situation or in order to perform
an invasive procedure.
To generate a safer, antidote-controllable VWF inhibi-
tor, we decided to exploit the properties of nucleic acid
ligands termed aptamers. Aptamers are single-stranded
nucleic acid molecules that can directly inhibit protein
function by binding to their targets with high affinity and
specificity (Nimjee et al., 2005a, 2005b). To isolate RNA
aptamers against VWF, we performed a modified version
of SELEX (systematic evolution of ligands by exponen-
tial enrichment) termed convergent SELEX. These ap-
tamers bind to VWF with high affinity (Kd  20 nM) and
inhibit platelet aggregation in platelet function analyzer
(PFA-100) and ristocetin-induced platelet aggregation
(RIPA) assays. Moreover, we have rationally designed
an antidote molecule that can quickly reverse above said
aptamers’ function. This antidote molecule can give




Convergent SELEX. The sequence of the starting RNA
combinatorial library was 5-GGGAGGACGATGCGG-
N40-CAGACGACTCGCTGAGGATCC-3, where N40
represents 40 completely random nucleotides. 2F cyti-
dine triphosphate and 2F uridine triphosphate (Trilink
Biotechnologies, San Diego, CA) were incorporated into
the RNA libraries by in vitro transcription in order to
confer nuclease resistance. The selection was carried out
in selection buffer E (20 mM HEPES, pH 7.4, 50 mM
NaCl, 2 mM CaCl2, and 0.1% bovine serum albumin
[BSA]) at 37°C until round P5V2 and then continued in
selection buffer F (20 mM HEPES, pH 7.4, 150 mM
NaCl, 2 mM CaCl2, and 0.1% BSA). RNA-VWF com-
plexes were separated from unbound RNA by passing
them over a nitrocellulose filter (BA 85, Whatman Inc.,
Florham Park, NJ).
Five rounds of SELEX were performed on the plasma
proteome followed by four rounds of convergent SELEX
as described by Layzer et al. (2007). Briefly, the starting
aptamer library (Sel2) was incubated with diluted normal
human plasma at 37°C for 15 minutes in selection buffer
E. Yeast tRNA was used to inhibit nonspecific binding of
the aptamer library to the plasma proteome. Bound RNA
aptamers were separated from unbound aptamers using a
nitrocellulose filter. After round 5 of plasma SELEX,
convergent SELEX using VWF was performed for 4
rounds (2 rounds in selection buffer E followed by 2
rounds in selection buffer F).
Antidote oligonucleotides
Antidote oligonucleotides were synthesized and puri-
fied by Dharmacon Research, Inc. (Lafayette, CO). 2-O-




Affinity constants (Kd values) were determined using
double-filter nitrocellulose filter binding assays (Rusconi
et al., 2000). All binding studies were performed in either
binding buffer E (20 mM HEPES, pH 7.4, 50 mM NaCl,
2 mM CaCl2, and 0.1% BSA) or binding buffer F (20
mM HEPES, pH 7.4, 150 mM NaCl, 2 mM CaCl2, and
0.1% BSA) at 37°C. Human purified VWF (factor VIII
free) was purchased from Haematologic Technologies
Inc. (Essex Junction, VT) and used in the double-filter ni-
trocellulose filter binding assay to determine the Kd of
every other round and individual clones. VWF SPI and
VWF SPIII domains were kindly provided by Dr. J. Evan
Sadler (Washington University, St. Louis, MO). Briefly,
RNA were dephosphorylated using bacterial alkaline
phosphatase (Gibco BRL, Gaithersberg, MD) and end-la-
beled at the 5 end with T4 polynucleotide kinase (New
England Biolabs, Beverly, MA) and [32P] ATP (Amer-
sham Pharmacia Biotech, Piscataway, NJ; Fitzwater and
Polisky, 1996). Direct binding was performed by incu-
bating 32P-RNA with VWF in physiologic buffer plus 1
mg/mL bovine serum albumin (BSA) at 37°C for 5 min-
utes. The fraction of the nucleic acid-protein complex
that bound to the nitrocellulose membrane was quantified
with a phosphoimager (Molecular Dynamics, Sunnyvale,
CA). Nonspecific binding of the radiolabeled nucleic
acid was subtracted out of the binding such that only spe-
cific binding remained (Wong and Lohman, 1993).
Platelet function analysis
PFA-100. The Platelet Function Analyzer, PFA-100
(Dade Behring, Deerfield, IL), measures platelet function
in terms of clot formation time. In this assay, we utilized
collagen/ADP cartridges to activate the platelets and
measure the amount of time taken to form a clot in anti-
coagulated whole blood (Harrison, 2005). Briefly, 840
L of whole blood was mixed with aptamer in platelet
binding buffer (150 mM NaCl; 20 mM Hepes pH: 7.4; 5
mM KCl; 1 mM MgCl2 and 1 mM CaCl2) and incubated
for 5 minutes at room temperature. This mixture was then
added to a collagen/ADP cartridge and tested for its clos-
ing time. The maximum closing time of the PFA-100 is
300 seconds. Antidote activity of the aptamer was mea-
sured by mixing whole blood with aptamer, incubating
for 5 minutes followed by addition of antidote or buffer,
and testing the mixture in the PFA-100.
Platelet aggregometry. A Chrono-log Whole Blood
Lumi Ionized Aggregometer (Chrono-log, Haverton, PA)
was used to provide a measurement of platelet aggrega-
tion in platelet-rich plasma (PRP). Briefly, PRP was iso-
lated from whole blood collected in 3.2% buffered
trisodium citrate tubes (BD Vacutainer Systems, Franklin
Lakes, NJ); aptamer was added and incubated with the
PRP for 5 minutes before testing. After calibrating the in-
strument, 5 L of agonist was added and transmission
was measured for 10 minutes.
Ristocetin-induced platelet aggregation. Ristocetin-in-
duced platelet aggregation (RIPA) was performed using
platelet-rich plasma (PRP) from healthy volunteers.
Clone VWF R9.3 or VWF R9.14 was mixed with 400 L
of PRP in a flat-bottom glass tube; ristocetin (Helena
Laboratories, Beaumont, TX) was added to a final con-
centration of 1.25 mg/mL. The PRP was stirred using a
steel stir bar at 37°C and turbidity was monitored as per-
cent light transmitted for 10 minutes.
Collagen-induced platelet aggregation. Collagen-in-
duced platelet aggregation (CIPA) was performed using
PRP from healthy volunteers. Clone VWF R9.3 or VWF
R9.14 was mixed with 400 L of PRP in a flat-bottom
glass tube and collagen was added to a final concentra-
tion of 2 g/mL. The PRP was stirred using a steel stir
bar at 37°C and turbidity was monitored as percent light
transmitted for 10 minutes.
ADP-induced platelet aggregation. ADP-induced
platelet aggregation (AIPA) was performed using PRP
from healthy volunteers. Clone VWF R9.3 or VWF
R9.14 was mixed with 400 L of PRP in a flat-bottom
glass tube and ADP was added to a final concentration of
10 M. The PRP was stirred using a steel stir bar at 37°C
and turbidity was monitored as percent light transmitted
for 6 minutes.
Thrombin-induced platelet aggregation. Thrombin-in-
duced platelet aggregation (TIPA) was performed using
PRP from healthy volunteers and SFLLRN peptide.
Clone VWF R9.3 or VWF R9.14 was mixed with 400 L
of PRP in a flat-bottom glass tube and SFLLRN was
added to a final concentration of 2 nM. The PRP was
stirred using a steel stir bar at 37°C and turbidity was
monitored as percent light transmitted for 6 minutes.
RESULTS
Five rounds of SELEX followed by four rounds of
convergent SELEX yielded aptamers that bind to
VWF with high affinity.
To isolate RNA aptamers against VWF, we performed
a modified version of SELEX. First, an RNA library con-
taining 2-flouropyrimidines was incubated with total
plasma proteins; the RNA ligands that bound to this pro-
teome were recovered. Four additional rounds of SELEX
were performed against the plasma proteome to generate
a focused library that was highly enriched for RNA 
ligands that bound plasma proteins. Next, convergent SE-
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LEX (Layzer, 2007) was performed to isolate those RNA
aptamers from the focused library that specifically bound
VWF. Such convergent SELEX progressed rapidly; the
affinity of the round 4 pool of aptamers had a Kd of 4.5 nM
for VWF (Fig. 1A). Next, the identity of the individual ap-
tamers was determined by cloning and sequencing. As
shown in Table 1, two sequences dominated following
round 4 of convergent SELEX against VWF (clones 9.3
and 9.4). These dominant clones, along with two less
abundant clones (9.18 and 9.14), were chosen for further
evaluation. To characterize the binding of these aptamers
to VWF, we performed nitrocellulose filter binding assays.
As shown in Table 1 and Figure 1B, three of the four
clones (9.3, 9.4, and 9.14) bound to VWF with high affin-
ity (Kd  20 nM) (Fig. 1B). Thus, by performing 5 rounds
of SELEX on the plasma proteome followed by 4 rounds
of convergent SELEX against VWF using the plasma pro-
teome-focused library, we identified aptamers that bound
to VWF with high affinity.
Clones VWF R9.3 and VWF R9.4 bind to the
VWF SPIII domain but not to the VWF SPI
domain; clone VWF R9.4 binds to both the 
VWF SPI and SPIII domains
To determine the specific binding domains of selected
aptamer clones on VWF, we performed studies using
VWF SPI and VWF SPIII domains. SPI and SPIII are 
V8 protease fragments of VWF from the N-terminus of
the protein. SPIII is 1365 residues in length (aa 1–1365)
containing domains from D mid-way through D4, in-
cluding the A1 domain. SPI represents the C-terminal
ONEY ET AL.268
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FIG. 1. Convergent systematic evolution of ligands by exponential enrichment (SELEX) yielded aptamers that bind to von
Willebrand factor (VWF) with high affinity. A: Progress of the convergent SELEX was followed using a nitrocellulose filter bind-
ing assay. Inverted triangles () represent the starting RNA library (Sel2). Squares () represent the plasma focused library. Tri-
angles () represent convergent SELEX round 2 and circles () represent convergent SELEX round 4. The X-axis represents
VWF concentration and the Y-axis represents the fraction of RNA bound to the protein. B: Binding affinities of VWF aptamers
R9.3, R9.4 and R9.14 were determined using a nitrocellulose filter binding assay. Squares () represent R9.3, triangles () repre-
sent R9.4 and inverted triangles () represent R9.14. Each data point was done in triplicate; error bars represent the standard error
of the mean (SEM) of the data. C: Binding of aptamers to VWF, VWF SPI, and VWF SPIII fragments was determined using a ni-
trocellulose filter binding assay. Aptamers R9.3 and R9.14 bind to both full length VWF and the VWF SPIII fragment but not to
the VWF SPI fragment. Aptamer R9.4 binds to full-length VWF, the VWF SPIII and the VWF SPI fragment. D: Cartoon depict-
ing VWF, its subunits and SPI and SPIII fragments. Binding sites for various ligands are indicated.
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455 residues of SPIII and contains mainly domain A3
and a part of domain D4 (Fig. 1D).
Clones VWF R9.3 and VWF R9.14 bound to the SPIII
fragment but not to the SPI fragment (Fig. 1C and 1D).
These results suggest that these aptamers bind proximal
to the positively charged A1 domain of VWF. The A1
domain is mainly involved in platelet aggregation since it
makes contact with the GP Ib subunit of platelet recep-
tor GP Ib-IX-V. Clone VWF R9.4 bound to both SPI and
SPIII domains, mapping its binding proximal to the VWF
A3 domain (Fig. 1C).
Clones VWF R9.3 and VWF R9.14 but not 
VWF R9.4 inhibited platelet function 
measured by PFA-100
To determine whether the isolated aptamers had any
effect on platelet activity, they were evaluated for their
ability to limit platelet-induced clot formation in a PFA-
100 assay. The PFA-100 instrument uses small mem-
branes coated with collagen/ADP or collagen/epineph-
rine to screen for the presence of platelet function
defects. As shown in Figure 2A, VWF aptamers R9.3 and
R9.14 inhibited platelet dependent clot formation com-
pletely in the PFA-100 assay (closing time  300 sec-
onds) at a concentration of 1 M. In contrast, VWF ap-
tamer R9.4, while having a Kd similar to R9.3 and R9.14,
had no activity (Fig. 2A). Next, to determine the mini-
mum effective dose of VWF aptamer R9.3 and VWF ap-
tamer R9.14, we performed a dose titration study. As
shown in Figure 2B, both aptamers completely inhibited
platelet function (CT  300 seconds) at concentrations
greater than 40 nM in normal whole blood in the PFA-
100 assay (Fig. 2B). Thus, at concentrations above 40
nM, these two aptamers inhibit platelet function to the
level seen in patients with severe VWD.
Clones VWF R9.3 and VWF R9.14 inhibited
platelet aggregation as measured by RIPA but
not by CIPA, AIPA, and TIPA
To confirm these findings and to determine the speci-
ficity of the VWF aptamers, we performed platelet aggre-
gation studies. First, we investigated the effects of VWF
aptamers R9.3 and R9.14 in a RIPA assay to determine if
the aptamers inhibit platelet function by blocking VWF’s
ability to interact with GP Ib-IX-V. Ristocetin was used
as a VWF antagonist because it binds specifically to
VWF in PRP and assists in VWF-mediated platelet acti-
vation/aggregation through the GP Ib-IX-V receptor. We
also evaluated other antagonists (collagen, ADP, and
thrombin) that activate platelets through pathways that
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TABLE 1. P5V4 APTAMER SEQUENCES
Frequency
Clone ID Variable region sequence (%) Kd
VWF R9.3 5-ATCGCGCTCTCCTGCTTAAGCAGCTATCAAATAGCCCACT-3 39 1.2 nM
VWF R9.4 5-TATAGACCACAGCCTGAGATTAACCACCAACCCAGGACT-3 36 1.9 nM
VWF R9.18 5-TGCTCCTTGGCCTTAGCCCTGGAACCATCAATCCTCTTCG-3 3 278 nM
VWF R9.14 5-TGGACGAACTGCCCTCAGCTACTTTCATGTTGCTGACGCA-3 1 12 nM
VWF R9.90 5-ACGNGTANACCTGCTACAATANCAGCCTAAATGGCCACT-3 1 N/D
VWF R9.66 5-ATCCCTGCCAAACATACTTTCGCTTTGGCTAGGACTCCCT-3 3 N/D
VWF R9.37 5-GCACCCCCTCGACAACGACCCTGTGCCCCTCGATCGACCA-3 2 N/D
VWF R9.54 5-CCCATTACGGCTT-CCTTGTATTCTTGGACAAGCCGCGACT-3 2 N/D
VWF R9.35 5-ACCCTTGACAACAACCCTTCCTCACCAACCCCTCCCAAC-3 1 N/D
VWF R9.81 5-ATACCCTCGACAACGACCCTATTCGCATGACACCTCTGTG-3 1 N/D
VWF R9.33 5-ATGAATCCTCCTGTCGAACAACAGCTGTTTCAGCCCAACT-3 1 N/D
VWF R9.93 5-GACCGACTGATTCGCACCAGACCACGACGTTATGGCCCAA-3 1 N/D
VWF R9.74 5-GTCGACTTAGCCCCGTGCTCGGCGCTTCACAGTCGACTAT-3 1 N/D
VWF R9.41 5-CGAGATCACACTGCCCCAATAGCCACTGAACTAGCGCGCA-3 1 N/D
VWF R9.46 5-ACCATTCGCGAGCACAACGCTTTGTACTCAACACTCCACG-3 1 N/D
VWF R9.49 5-ACCGTTCAGAAATGACCCCACGCACATCCATCCCTGAGCT-3 1 N/D
VWF R9.97 5-ACGTGATCCTCGGACCCAGCATTGCATTATATGCGCCCCT N/D
VWF R9.95 5-ACTCTCAGCCCATGTGCCTCAACCAAGGCACGGCTTGCTC-3 1 N/D
VWF R9.62 5-CACCCTTCACCCGAACCCTGCCC-ACG-ACCCCACACCCCGC-3 1 N/D
VWF R9.57 5-ATGACCAGCCCCTCGACAACGACCCTGCTGGCTCAACCGTT-3 1 N/D
VWF R9.118 5-GACCGCCGCNNCCGACCCNAGNNNTGCTGTGTNCGCTCCGCC-3 1 N/D
ND, not determined.
are not dependent on the VWF-GP Ib-IX-V interaction to
determine if the aptamers had any inhibitory effect on
these additional activation pathways. As shown in Figure
2C, VWF aptamers R9.3 and R9.14 completely inhibited
RIPA (at a concentration of 250 nM), illustrating that the
aptamers can potently inhibit the VWF-GP Ib-IX-V in-
teraction. In contrast, the aptamers had no effect in colla-
gen, ADP or thrombin induced platelet aggregation (Fig.
2C). Thus, VWF aptamers R9.3 and R9.14 inhibit
platelet function by specifically blocking VWF-GP Ib-
IX-V-mediated platelet activation and aggregation.
Antidote oligonucleotide 6 (AO6) can reverse
VWF R9.14 binding to VWF to background levels
Six different antidote oligonucleotides (AO1–6) were
designed to bind to VWF aptamer R9.14 through Wat-
son-Crick base pairing rules (Fig. 3A). This strategy has
been successfully employed in our laboratory to design
an antidote to control the activity of an aptamer to factor
IXa (Rusconi et al., 2002, 2004; Nimjee et al., 2006). To
determine if the antidote oligonucleotides could inhibit
aptamer binding to VWF, we evaluated them in a nitro-
cellulose filter binding assay. As shown in Figure 3B, the
most effective antidote for VWF aptamer R9.14 is AO6.
This antidote can reverse VWF aptamer R9.14’s ability
to bind VWF to background levels (Fig. 3B).
AO6 can reverse the effects of VWF R9.14
completely in a PFA-100 assay
Since AO6 can reverse VWF aptamer 9.14 binding to
VWF, we wanted to next determine if the antidote could
also reverse the aptamer’s activity in a whole blood clin-
ical laboratory assay. To that end, we tested the ability of
AO6 to inhibit VWF aptamer 9.14 in a PFA-100 assay.
As shown in Figure 4A, the antidote can reverse the ac-
tivity of the aptamer in a dose-dependent manner. More-
over, the antidote is able to completely reverse the an-
tiplatelet effects of the VWF aptamer R9.14 at a 40-fold
excess of aptamer concentration. In contrast, a scrambled
version of the antidote oligonucleotide (Scr AO6) had no
effect on aptamer activity (Fig. 4A). Thus, antidote AO6
is able to restore platelet function in a whole blood assay
back to normal levels, even in the presence of enough
VWF aptamer 9.14 (40 nM) to impede platelet function
























































































































































































































































FIG. 2. Von Willebrand factor (VWF) aptamers R9.3 and
R9.14 inhibit platelet aggregation by blocking the VWF–GP
Ib-IX-V interaction. A: The function of VWF aptamers R9.3,
R9.4, and R9.14 was measured at a 1 M concentration in a
PFA-100 assay. Platelet buffer and starting aptamer library
(Sel2) were used as negative controls. Error bars represent the
range of data. Each data point was done in triplicate. B: Vary-
ing concentrations of VWF aptamers R9.3 and R9.14 were
added to normal whole blood; closing times were measured in a
PFA-100 assay using collagen/ADP cartridges. Error bars rep-
resent the range of data. Each data point was done in triplicate.
C: VWF aptamers R9.3 and VWF R9.14 were tested in risto-
cetin, collagen, ADP, and thrombin (SFLLRN) induced platelet
aggregation. Filled bars represent percent aggregation in nor-
mal platelet rich plasma. Error bars represent the range of data;
each data point was done in triplicate.
AO6 can quickly reverse the effects of VWF
R9.14 for a sustained period of time in a PFA-
100 assay
For such an antidote to be useful clinically, the antidote
should be able to act quickly and for a prolonged period
of time. To determine how rapidly AO6 could reverse the
aptamer and how long such reversal is sustained, we per-
formed a time course assay using the PFA-100. As
shown in Figure 4B, AO6 can rapidly reverse the effects
of VWF aptamer R9.14 in less than 2 minutes. Moreover,
once the antiplatelet activity is reversed, the antidote
maintained its ability to sustainably inhibit the aptamer
for greater than 4 hours (Fig. 4C). We could not test AO
activity for more than 4 hours due to platelet degradation
over such time. These results demonstrate that AO6 can
rapidly and durably reverse the effects of VWF aptamer
R9.14.
DISCUSSION
Aptamers are single-stranded nucleic acid molecules that
can directly inhibit protein function by binding to their tar-
get with high affinity and specificity. To date, a number of
proteins involved in coagulation have been targeted by ap-
tamers, successfully yielding anticoagulant molecules with
therapeutic potential (Rusconi et al., 2000a, 2002b; Becker
et al., 2005; Nimjee et al., 2005). Aptamers represent an at-
tractive class of therapeutic compounds for numerous rea-
sons. They are relatively small (8 kd to 15 kd) synthetic
compounds that possess high affinity and specificity for
their target proteins (equilibrium dissociation constants
ranging from 0.05–40 nM). Thus, they embody the affinity
properties of monoclonal antibodies with the chemical pro-
duction properties of small peptides. In addition, preclinical
and clinical studies to date have shown that aptamers and
compounds of similar composition are well tolerated,
exhibit low or no immunogenicity, and are suitable for re-
peated administration as therapeutic compounds (Eyetech-
StudyGroup 2002, 2003; Dyke et al., 2006). Moreover,
bioavailability and clearance mechanisms of aptamers can
be rationally altered by molecular modifications to the li-
gand (i.e., cholesterol or polyethylene glycol). Most impor-
tantly, Rusconi et al. (2002, 2004) and Nimjee et al. (2006)
have shown that antidote oligonucleotides can be rationally
designed that negate the effect of aptamers in vitro and in
vivo. Antiplatelet agents currently used in clinics can have a
major bleeding side effect which can increase mortality and
morbidity and significantly limit their use (Jackson and
Schoenwaelder, 2003). Using antidotes is the most effec-
tive and reliable way to control drug action and can reduce
bleeding associated with current antiplatelet agent use in
clinics, enhancing safety and reducing morbidity and mor-
tality.
We used a technique termed convergent SELEX and
isolated a number of aptamers that bind to VWF with
high affinity. Furthermore, we showed that two of these
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5'-GGGAGGACGAUGCGG-UGGACGAACUGCCCUCAGCUACUUUCAUGUUGCUGACGCA---CAGACGACUCGCUGAGGAUCC-3'
5' Fixed Region
AO1 AO2 AO3 AO4 AO5
AO6
Variable Region 3' Fixed Region














FIG. 3. Antidote oligonucleotides to R9.14 can inhibit ap-
tamer binding to von Willebrand factor (VWF). A: Cartoon de-
picting the antidote design to aptamer VWF R9.14. Black bars
depict the positions of sequence complementarities. B: Rever-
sal of aptamer VWF R9.14 binding to VWF was accomplished
by antidote oligonucleotide 6 (AO6) (triangles) but not by AO5
(inverted triangles). AO6 and AO5 together (diamonds) also in-
hibit aptamer binding to VWF. The starting library (Sel2; cir-
cles) was used as a control.
clones inhibit VWF mediated platelet activation and ag-
gregation in ex vivo assays. Coincidentally, we have
demonstrated that both of these functional aptamers bind
to the same region of VWF involved in platelet aggrega-
tion using VWF SPI and SPIII fragments. To test the
characteristics of these aptamers in functional assays, we
utilized a PFA-100 instrument. PFA-100 simulates
platelet function in whole blood under high shear stress
and is particularly sensitive to VWF defects (Harrison,
2005). Both clone R9.3 and R9.14 completely inhibited
platelet plug formation in PFA-100 at concentrations
greater than 40 nM (closing time 300 seconds). More-
over, we tested these aptamers in ristocetin, ADP, throm-
bin (SFLLRN peptide), and collagen-mediated platelet
aggregation assays for pathway specificity. Both of these
clones inhibited RIPA at greater than 250 nM concentra-
tion but had no significant effect in other agonist medi-
ated aggregation assays. These experiments show that
both clone R9.3 and clone R9.14 bind VWF with high
affinity and inhibit platelet aggregation through inhibi-
tion of the GP Ib-IX-V–VWF interaction. This interac-
tion is especially important around areas of high shear
stress (i.e., stenosed arteries) and is a valid target for anti-
platelet therapy.
Antidote control gives physicians added control over
drug activity and provides a safer means for antiplatelet
therapy. To further improve the safety of the lead mole-
cule R9.14, we rationally designed an antidote oligonu-
cleotide using the properties inherent to nucleic acids
(Rusconi et al. 2002, 2004; Nimjee et al., 2006). Antidote
oligonucleotides bind to their target aptamer through
Watson-Crick base pairing, thus changing the aptamer’s
conformational shape and inhibiting binding to its target,
therefore reversing its activity. We designed six different
antidote oligonucleotides and tested their activity in a ni-
trocellulose filter binding assay. AO6 was the most effec-
tive in inhibiting aptamer binding to VWF, completely
reducing it to nonspecific, background levels. To test the
effect of antidote AO6 on clone R9.14, we tested the pair
in PFA-100. AO6 completely reverses the antiplatelet ef-
fect of R9.14 in less than 2 minutes and is effective for at
least 4 hours. This aptamer-antidote pair can potentially




























































































































































































































































































































FIG. 4. Antidote oligonucleotides to aptamer von Willebrand
factor (VWF) R9.14 can reverse aptamer function rapidly and
for a prolonged period of time. A: Antidote oligonucleotide 6
(AO6) completely reverses aptamer function in a PFA-100 as-
say (black bars) at a 40:1 ratio. A scrambled antidote oligonu-
cleotide was used as a negative control (grey bars). Error bars
represent the range of data. Each data point was done in tripli-
cate. B: AO6 achieved complete reversal of aptamer VWF
R9.14 function in a PFA-100 assay in 2 minutes. AO6 was used
at a 40:1 ratio to VWF R9.14 (40 nM). Error bars represent the
range of data. Each data point was done in triplicate. C: AO6
inhibits aptamer VWF R9.14 function for 4 hours in a PFA-100
assay (black bars). A scrambled antidote oligonucleotide was
used as a negative control (grey bars). Error bars represent the
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